Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Armand

Showing results (21-30 of 205) with videos related to

Pageof 21
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 2015
Pharmacokinetic and pharmacodynamic end points with anti-VEGFR: the more it hurts, the more it works?O Mir, S Dumont, J-P Armand
Therapie|November 7, 1998
[Recommendations for the study of drug combination therapy for the treatment of AIDS and cancer. Round Table No 7 at Giens XIII]J P Armand, J Dormont, A Schwebig
Bulletin Du Cancer|February 5, 1999
[Irinotecan: various administration schedules, study of drug combinations, phase I experience]V Boige, E Raymond, J P Armand
Drugs|December 29, 2000
Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapyE Raymond, S Faivre, J P Armand
La Revue Du Praticien|May 15, 1994
[Suramin. A new role for an old drug]P Soulie, E Cvitkovic, J P Armand
Cancer Treatment and Research|January 1, 1989
Nasopharyngeal cancer, undifferentiated type: the medical oncologist's viewpointE Cvitkovic, H Boussen, J P Armand
Bulletin Du Cancer|November 26, 1999
[Rapamycin and CCI-779]J Alexandre, E Raymond, J P Armand
Hematology/Oncology Clinics of North America|August 1, 1991
Nasopharyngeal carcinoma. Biology, natural history, and therapeutic implicationsE Cvitkovic, M Bachouchi, J P Armand
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2004
Molecular targeting: targeting angiogenesis in solid tumorsJ-C Soria, J Fayette, J-P Armand
European Journal of Cancer (Oxford, England : 1990)|January 25, 2000
Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: preliminary results of phase I clinical trialsJ P Armand, L Seymour, T R Evans
Pageof 21

Showing results (21-30 of 205) with videos related to

Sort By:
Pageof 21
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 2015
Pharmacokinetic and pharmacodynamic end points with anti-VEGFR: the more it hurts, the more it works?O Mir, S Dumont, J-P Armand
Therapie|November 7, 1998
[Recommendations for the study of drug combination therapy for the treatment of AIDS and cancer. Round Table No 7 at Giens XIII]J P Armand, J Dormont, A Schwebig
Bulletin Du Cancer|February 5, 1999
[Irinotecan: various administration schedules, study of drug combinations, phase I experience]V Boige, E Raymond, J P Armand
Drugs|December 29, 2000
Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapyE Raymond, S Faivre, J P Armand
La Revue Du Praticien|May 15, 1994
[Suramin. A new role for an old drug]P Soulie, E Cvitkovic, J P Armand
Cancer Treatment and Research|January 1, 1989
Nasopharyngeal cancer, undifferentiated type: the medical oncologist's viewpointE Cvitkovic, H Boussen, J P Armand
Bulletin Du Cancer|November 26, 1999
[Rapamycin and CCI-779]J Alexandre, E Raymond, J P Armand
Hematology/Oncology Clinics of North America|August 1, 1991
Nasopharyngeal carcinoma. Biology, natural history, and therapeutic implicationsE Cvitkovic, M Bachouchi, J P Armand
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2004
Molecular targeting: targeting angiogenesis in solid tumorsJ-C Soria, J Fayette, J-P Armand
European Journal of Cancer (Oxford, England : 1990)|January 25, 2000
Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: preliminary results of phase I clinical trialsJ P Armand, L Seymour, T R Evans
Pageof 21